Fulminant Type 1 Diabetes:The Clinical Features and Treatment Strategy

ZHOU Jian,BAO Yu-qian,LI Ming,LIU Fang,CHEN Hai-bing,HAN Jun-feng,LU Wei,MA Xiao-jing,HU Cheng,XIANG Kun-san,JIA Wei-ping

DOI: https://doi.org/10.3760/cma.j.issn.1674-5809.2009.01.011

2009-01-01

Abstract:Objective To enhance the understanding of fulminant type 1 diabetes (FT1 DM). Methods Clinical and laboratory data of 3 patients diagnosed as FT1 DM in our hospital from January 2007 to March 2008 were retrospectively analyzed. Results (1) All of 3 cases were males aged from 29 to 43 years old with body mass index ranged from 21.5 to 23.3 kg/m2. (2)They were developed to ketoacidosis rapidly after the appearance of diabetic symptoms in 2-4 days. One case had a cardiac arrest. (3) At the stage of onset, the plasma glucose level were above 38 mmol/L, glycosylated hemoglobin ranged from 6.2% to 6.3% and serum glycated albumin ranged from 15% to 24%. (4) Serum glutamic acid deearboxylase antibody and protein tyrosine phosphatase antibody were negative. (5) Their β-cell functions were extremely poor confirmed by a standard test meal and arginine stimulation test. (6) Serum hemodiastase (263-2319 U/L) and lipase (812-859 U/L) were high. Ultrasound and computed tomography showed a normal pancreas. (7) Serum creatinekinase level (1283-12 239 U/L) was extremely high. One case had rhabdomyolysis confirmed by biopsy at gastrocnemius muscle. Serum liver enzyme and myocardial enzyme pedigree were risen significantly. (8) Case 1 was treated with multiple daily insulin injections (MDI) when he was discharged. Case 2 was treated with continuous subcutaneous insulin infusion (CSII). Case 3 was treated with MDI at the beginning of the therapy and transferred to CSII later. Comparing glycemic parameters of continuous glucose monitoring, not only mean level of 24 h blood glucose and intra-day giycemic variability (mean amplitude of giycemic excursions and Schlichtkrull's M-value) but also day-to-day glycemic variability (absolute means of daily differences) were indicated case 2 < case 3 (CSII) < case 1 < case 3 (MDI). Conclusions (1) FT1 DM patients had clinical feathers of abrupt onset, serious metabolic disorders, serious impaired islet β-cell function, complicated with multiple organ impair, which required special attention by all medical practitioners. (2) FTI DM patients had a great glycaemia excursion and were subject to hypoglycaemia. Maybe long-term CSII regimen was needed to improve the prognosis.